# Lluis Pareras

> Lluis Pareras is a seed investor at Invivo Capital Partners backing Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners)
- Location: Barcelona, Spain
- Total investments: 14
- Last investment: Jul 2026
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://es.linkedin.com/in/lluispareras

Lluis Pareras is a seed investor at Invivo Capital Partners in Barcelona focused on Biotechnology and Pharmaceutical. Dr. Lluís Pareras serves as the Founding Partner at Invivo Capital Partners. He is currently employed at Riva y García Private Equity. He has been a Board Member of Versantis AG since March 29, 2017.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 43% |
| Pharmaceutical | 3 | 21% |
| Health Care | 2 | 14% |
| Therapeutics | 2 | 14% |
| Genetics | 1 | 7% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 50% |
| Series A | 3 | 21% |
| Series B | 1 | 7% |
| Venture - Series Unknown | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 6 | 43% |
| France | 1 | 7% |
| Denmark | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M | Series B | Sep 17, 2025 |  |
| Integra Therapeutics | Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M | Seed | Sep 08, 2025 |  |
| Neumirna Therapeutics | Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions. | $20.6M | Series A | Jan 08, 2025 |  |
| Gyala Therapeutics | Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytesare obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas. | $3.3M | Venture - Series Unknown | Oct 14, 2024 |  |
| Corteria Pharmaceuticals | Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $69.5M | Series A | Sep 07, 2023 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $46.5M | Series B | May 03, 2023 |  |
| Corteria Pharmaceuticals | Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $13.6M | Seed | Dec 09, 2021 |  |
| Integra Therapeutics | Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $5.1M | Seed | Dec 02, 2021 |  |
| Telomere Therapeutics | Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis | $1.8M | Seed | Dec 01, 2020 |  |

10 of 14 investments shown.

## Co-investors
- [AdBio partners](https://shizune.co/investors/profile/advent-france-biotechnology) — VC Fund, 5 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 4 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 4 deals together
- [Columbus Venture Partners](https://shizune.co/investors/profile/columbus-venture-partners) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Centre for the Development of Industrial Technology (CDTI)](https://shizune.co/investors/profile/centre-for-the-development-of-industrial-technology-cdti) — VC Fund, 2 deals together

## About Invivo Capital Partners

VC Fund · Barcelona, Spain

Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.

2 contacts available at Invivo Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Albert Ferrer | Founding Partner | https://shizune.co/investors/profile/albert-ferrer |
| Lluis Pareras | Partner | https://shizune.co/investors/profile/lluis-pareras |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Lluis Pareras invest in?

Lluis Pareras invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lluis Pareras last invest?

The most recent investment recorded for Lluis Pareras closed in Jul 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co